Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

University of Aarhus14 enrolled

Overview

Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatocellular Carcinoma Cholangiocarcinoma Metastases Stereotactic Body Radiotherapy

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * liver tumor * referred for stereotactic radiation therapy * age \> 18 years Exclusion Criteria: * Impaired kidney function * Pregnancy

Outcomes

Primary Outcomes

Uptake of FDGal

Volumetric uptake of FDGal can be measured is measured by PET/CT

Time frame: Before, 1 month and 3 months after stereotactic radiotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.